MA54192A - Vaccins à arn contre le cancer - Google Patents
Vaccins à arn contre le cancerInfo
- Publication number
- MA54192A MA54192A MA054192A MA54192A MA54192A MA 54192 A MA54192 A MA 54192A MA 054192 A MA054192 A MA 054192A MA 54192 A MA54192 A MA 54192A MA 54192 A MA54192 A MA 54192A
- Authority
- MA
- Morocco
- Prior art keywords
- against cancer
- vaccines against
- rna vaccines
- rna
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862757057P | 2018-11-07 | 2018-11-07 | |
| US201962813900P | 2019-03-05 | 2019-03-05 | |
| US201962855335P | 2019-05-31 | 2019-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54192A true MA54192A (fr) | 2021-09-15 |
Family
ID=70612163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054192A MA54192A (fr) | 2018-11-07 | 2019-11-07 | Vaccins à arn contre le cancer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220125899A1 (fr) |
| EP (1) | EP3876947A4 (fr) |
| JP (2) | JP2022506839A (fr) |
| AU (1) | AU2019374818B2 (fr) |
| CA (1) | CA3118947A1 (fr) |
| MA (1) | MA54192A (fr) |
| WO (1) | WO2020097291A1 (fr) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| EP3328394A4 (fr) | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | Arn épitope peptidiques concatémériques |
| WO2017031232A1 (fr) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Procédés de préparation de particules et compositions associées |
| EP3364949A4 (fr) | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | Vaccins anticancéreux |
| DE20164728T1 (de) | 2015-10-22 | 2021-09-30 | Modernatx, Inc. | Impfstoffe gegen atemwegsvirus |
| EP3364981A4 (fr) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | Vaccin contre le cytomégalovirus humain |
| WO2017070624A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins contre des maladies tropicales |
| SG11201803360UA (en) | 2015-10-22 | 2018-05-30 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv) |
| DK3386484T3 (da) | 2015-12-10 | 2022-07-04 | Modernatx Inc | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler |
| US12128113B2 (en) | 2016-05-18 | 2024-10-29 | Modernatx, Inc. | Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome |
| SG11201901941YA (en) | 2016-09-14 | 2019-04-29 | Modernatx Inc | High purity rna compositions and methods for preparation thereof |
| EP3528821A4 (fr) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | Vaccin contre le cytomégalovirus humain |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| EP3551193A4 (fr) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | Vaccins à acide nucléique contre des virus respiratoires |
| EP3555289A1 (fr) | 2016-12-13 | 2019-10-23 | ModernaTX, Inc. | Purification par affinité d'arn |
| WO2018148381A1 (fr) * | 2017-02-07 | 2018-08-16 | Nantcell, Inc. | Maximisation de la mémoire de cellules t, compositions et méthodes associées |
| WO2018170256A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus de l'herpès simplex |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018170260A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus respiratoire syncytial |
| WO2018170270A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus varicelle-zona |
| WO2018170347A1 (fr) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Vaccins à base d'arn contre des maladies zoonotiques |
| MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| WO2019036685A1 (fr) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | Procédés pour analyse par clhp |
| EP3668977A4 (fr) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | Procédés analytiques par hplc |
| WO2019036682A1 (fr) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | Variants d'arn polymérase |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| EP3681514A4 (fr) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | Vaccins à arn contre le virus zika |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| CN112996854B (zh) | 2018-09-19 | 2024-08-30 | 摩登纳特斯有限公司 | 高纯度peg脂质和其用途 |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CN113939282A (zh) | 2019-01-31 | 2022-01-14 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| MX2021010075A (es) | 2019-02-20 | 2021-12-10 | Modernatx Inc | Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales. |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| MX2021011031A (es) | 2019-03-11 | 2021-12-10 | Modernatx Inc | Proceso de transcripción in vitro en lotes alimentados. |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| EP4061405A1 (fr) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccins basés sur les mutants du gène calr et de la protéine jak2 et leurs utilisations |
| CN118490818A (zh) | 2020-04-22 | 2024-08-16 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| EP4175664A2 (fr) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Néo-antigènes prostatiques et leurs utilisations |
| WO2022009049A1 (fr) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Néo-antigènes prostatiques et leurs utilisations |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4228679A1 (fr) * | 2020-10-14 | 2023-08-23 | Rnaimmune, Inc. | Vaccins contre le cancer à arnm pan-ras |
| WO2022125511A1 (fr) * | 2020-12-07 | 2022-06-16 | Iogenetics, Llc | Administration de vaccins antitumoraux |
| WO2022150717A1 (fr) | 2021-01-11 | 2022-07-14 | Modernatx, Inc. | Vaccins contre le virus de la grippe à arn saisonnière |
| WO2022187424A1 (fr) * | 2021-03-04 | 2022-09-09 | Helix Nanotechnologies, Inc. | Compositions comprenant des adjuvants de sbi et leurs procédés d'utilisation |
| WO2022197599A1 (fr) * | 2021-03-18 | 2022-09-22 | Ne1 Inc. | Vaccin contre le cancer et son procédé d'utilisation |
| EP4326227A1 (fr) | 2021-04-23 | 2024-02-28 | ModernaTX, Inc. | Formulations stabilisées |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| EP4147712A1 (fr) * | 2021-09-13 | 2023-03-15 | OncoDNA | Procédé pour générer un groupe d'adn à double brin codant pour des néo-antigènes d'une tumeur d'un patient |
| CA3230564A1 (fr) | 2021-09-13 | 2023-03-16 | Jean-Pol DETIFFE | Procede de generation de neo-antigenes personnalises d'une tumeur d'un patient |
| EP4147713A1 (fr) * | 2021-09-13 | 2023-03-15 | OncoDNA | Vaccin arn comprenant un groupe d'arn généré à partir d'un groupe d'adn à double brin |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| JPWO2024038857A1 (fr) | 2022-08-16 | 2024-02-22 | ||
| EP4364752A1 (fr) | 2022-11-07 | 2024-05-08 | OncoDNA | Vaccin ameliore |
| EP4648793A1 (fr) * | 2023-01-11 | 2025-11-19 | ModernaTX, Inc. | Vaccins anticancéreux personnalisés |
| JP2026517228A (ja) | 2023-05-17 | 2026-05-28 | テサロ, インコーポレイテッド | がんの治療におけるポリadpリボースポリメラーゼ(parp)阻害剤の新規使用 |
| WO2025087266A1 (fr) | 2023-10-23 | 2025-05-01 | Abogen Biosciences (Shanghai) Co., Ltd. | Cassettes d'arnm immunomodulatrices et leurs utilisations |
| WO2025117816A1 (fr) * | 2023-12-01 | 2025-06-05 | Recode Therapeutics, Inc. | Compositions de nanoparticules lipidiques et leurs utilisations |
| CN121064279A (zh) * | 2024-06-04 | 2025-12-05 | 复旦大学附属中山医院 | 一种抗肝癌hla-a*11型疫苗及其制备方法和应用 |
| WO2026064370A1 (fr) * | 2024-09-18 | 2026-03-26 | Modernatx, Inc. | Vaccins néoantigéniques individualisés pour le traitement du cancer du poumon non à petites cellules |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012116715A1 (fr) * | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination chez des nouveaux-nés et des enfants en bas âge |
| LT2714071T (lt) * | 2011-05-24 | 2019-10-10 | Biontech Rna Pharmaceuticals Gmbh | Individualizuotos vakcinos nuo vėžio |
| AU2013351542B2 (en) * | 2012-11-28 | 2018-08-09 | BioNTech SE | Individualized vaccines for cancer |
| EP3578200A1 (fr) * | 2013-02-22 | 2019-12-11 | CureVac AG | Combinaison de vaccination et d'inhibition de la voie pd-1 |
| AU2014251207B2 (en) * | 2013-04-07 | 2019-06-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
| DK3294326T3 (da) * | 2015-05-15 | 2021-05-31 | Curevac Ag | Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion |
| EP3328394A4 (fr) * | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | Arn épitope peptidiques concatémériques |
| EP3364949A4 (fr) * | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | Vaccins anticancéreux |
| WO2018115525A1 (fr) * | 2016-12-23 | 2018-06-28 | Curevac Ag | Vaccin contre le virus de lassa |
| KR102627347B1 (ko) * | 2017-01-27 | 2024-01-22 | 더 메서디스트 하스피틀 | 면역 요법을 위한 코어/쉘 구조 플랫폼 |
| CA3052255A1 (fr) * | 2017-02-01 | 2018-08-09 | Modernatx, Inc. | Vaccins anticancereux a arn |
| CA3050614A1 (fr) * | 2017-03-17 | 2018-09-20 | Curevac Ag | Vaccin a arn et inhibiteurs de points de controle immunitaires pour une therapie anticancereuse combinee |
-
2019
- 2019-11-07 MA MA054192A patent/MA54192A/fr unknown
- 2019-11-07 AU AU2019374818A patent/AU2019374818B2/en active Active
- 2019-11-07 CA CA3118947A patent/CA3118947A1/fr active Pending
- 2019-11-07 EP EP19882134.0A patent/EP3876947A4/fr active Pending
- 2019-11-07 US US17/291,947 patent/US20220125899A1/en active Pending
- 2019-11-07 WO PCT/US2019/060208 patent/WO2020097291A1/fr not_active Ceased
- 2019-11-07 JP JP2021524449A patent/JP2022506839A/ja active Pending
-
2025
- 2025-02-04 JP JP2025016804A patent/JP2025071108A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025071108A (ja) | 2025-05-02 |
| AU2019374818A1 (en) | 2021-05-27 |
| EP3876947A1 (fr) | 2021-09-15 |
| WO2020097291A1 (fr) | 2020-05-14 |
| EP3876947A4 (fr) | 2022-08-31 |
| AU2019374818B2 (en) | 2026-04-30 |
| US20220125899A1 (en) | 2022-04-28 |
| CA3118947A1 (fr) | 2020-05-14 |
| JP2022506839A (ja) | 2022-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3876947A4 (fr) | Vaccins à arn contre le cancer | |
| MA50253A (fr) | Vaccins à arn contre le virus zika | |
| MA47401A (fr) | Vaccins anticancéreux à arn | |
| EP4153730A4 (fr) | Vaccins contre le sars-cov-2 | |
| MA47680A (fr) | Arn thérapeutique | |
| IL299169A (en) | Self-amplification of Rana SARS-Covid-2 vaccine | |
| EP3324979A4 (fr) | Vaccins contre une maladie infectieuse | |
| EP3773649A4 (fr) | Vaccins anticancéreux personnalisés | |
| SG10201913631TA (en) | Rna for cancer therapy | |
| SMT202400506T1 (it) | Terapia genica | |
| MA54868A (fr) | Arn thérapeutique contre le cancer de la prostate | |
| IL292272A (en) | Cancer vaccine | |
| PT3612237T (pt) | Terapia genética | |
| MA52180A (fr) | Vaccins thérapeutiques anti-abêta | |
| IL279685A (en) | Gene therapy | |
| EP3919072A4 (fr) | Préparation vaccinale contre le cancer | |
| MA47122A (fr) | Vaccin à adn multi-épitope contre la cowdriose | |
| EP3500280A4 (fr) | Vaccins contre des virus | |
| DK3405212T3 (da) | Cancervacciner | |
| EP3777828A4 (fr) | Médicament anti-cancéreux à base de surfactant pulmonaire | |
| GB201802326D0 (en) | Gene therapy | |
| SG11202107203UA (en) | Mrna vaccine | |
| GB201817470D0 (en) | Gene therapy | |
| IL260988A (en) | Ptps-based vaccines against cancer | |
| GB202019916D0 (en) | RNA vaccine |